Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
A Phase 1a/1b Dose Escalation and Expansion Study of SC-003 as a Single-Agent and in Combination With ABBV-181 in Subjects With Platinum-Resistant/ Refractory Ovarian Cancer
Sponsor: Stemcentrx
Terminated
Strategic Considerations
Other terminated trials from Stemcentrx
More terminations from Stemcentrx
This PHASE1 trial investigates Ovarian Cancer and is currently terminated or withdrawn. Stemcentrx leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Feb 2019 — Jan 2021 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
▶ Show 9 earlier versions
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2018 — May 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE1
-
Sep 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
Jul 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stemcentrx
For direct contact, visit the study record on ClinicalTrials.gov .